System announced $20 million in new funding from seven investors to expand access to regulated peptide treatments and build its vertically integrated supply chain.
- Amount
- $20M
- Announced
- 9 September 2026
- Investors
- Patron Fund, Will Ventures, Vine, Courtside, Daybreak, SV Angel, RiverPark Ventures
- Use of funds
- Fresh capital will give more people access to peptide treatments historically reserved for select patients
- Checked
- Announced by the company